Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03147287 · ClinicalTrials.gov registry record · Phase 2
Palbociclib After CDK and Endocrine Therapy (PACE)
A Phase 2 study of Metastatic Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT03147287: Active Phase 2 study of Metastatic Breast Cancer, sponsored by Dana-Farber Cancer Institute.
NCT03147287 is a Phase 2 study of Metastatic Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 220 participants, roughly in line with the 203-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03147287, a Phase 2 study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: -Fulvestrant -Fulvestrant with Palbociclib -Fulvestrant with Palbociclib and Avelumab
Primary Outcome
Progression-Free Survival (PFS), according to RECIST v1.1 criteria (investigator assessment): the time from randomization to the earlier of progression or death due to any cause. Participants alive without disease progression were censored at date of last disease assessment (tumor assessments). The date of progression was the first date that recurrent or progressive disease was objectively documented; if death was the defining event, it must have happened within 2 intervals of the last disease a
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG Palbociclib
- DRUG Avelumab
Study Locations (20)
Massachusetts
- Boston Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
- Dana-Farber at St. Elizabeth's Medical Center - Brighton
- DF/BWCC at Milford Regional Medical Center - Milford
- DF/BWCC in clinical affiliation with South Shore Hospital - South Weymouth
Kansas
- The University of Kansas Cancer Center - North - Kansas City
- The University of Kansas Cancer Center - Overland Park - Overland Park
- The University of Kansas Cancer Center - Westwood
Missouri
- The University of Kansas Cancer Center - Lee's Summit - Lee's Summit
- Washington University - St Louis
Florida
- University of Miami - Miami
Georgia
- Emory University - Winship Cancer Institute - Atlanta
Illinois
- Northwestern University - Chicago
Indiana
- Indiana University - Indianapolis
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT03147287 still lists
NCT03147287 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 203-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Fulvestrant is the first listed.
NCT03147287 names 20 study sites across 13 states, led by Massachusetts, Kansas, Missouri.
Frequently Asked Questions
What is clinical trial NCT03147287 about?
NCT03147287 is a clinical study titled "Palbociclib After CDK and Endocrine Therapy (PACE)". This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: -Fulvestrant -Fulvestrant with Palbociclib -Fulvestrant with Palbociclib and Avelumab
What is the current status of trial NCT03147287?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2017-09-05. Estimated completion is 2026-06-30.
What conditions does trial NCT03147287 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT03147287?
The interventions under investigation include: Fulvestrant (DRUG), Palbociclib (DRUG), Avelumab (DRUG).
Who is sponsoring clinical trial NCT03147287?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03147287 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03147287's enrollment target sits among peer trials
220 27th of 139 higher than 113 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI